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Abstract 
Purpose: To investigate the effect of Lycii Fructus polysaccharides (LFPS) on ovulation failure. 
Methods: A rat model of ovulation failure was established by intragastric administration of hydroxyurea 
(300 mg/kg). Rats with ovulation failure then received LFPS via oral administration at doses of 100, 200, 
or 400 mg/kg. The body, uterus and ovary of each rat were weighed using electronic scales. The 
hypothalamic-pituitary-ovarian (HPO) axis hormones, including estradiol (E2) level, follicle-stimulating 
hormone (FSH) activity, and luteinizing hormone (LH) activity in the serum of each rat were determined 
by enzyme-linked immunosorbent assay (ELISA). The levels of pro-apoptotic proteins (Fas, FasL, 
FADD, c-caspase-8, c-caspase-10, c-caspase-3, c-caspase-6, and c-caspase-7) in the ovarian tissue of 
each rat were detected by western blot. 
Results: Hydroxyurea reduced significantly (p < 0.01) uterus and ovary indices (uterus or ovary 
weight/body weight) (0.119 and 0.026 %), E2 level (3.42 pmol/L), and FSH and LH activities (2.28 and 
2.76 U/L), compared with those in the normal group (0.169 and 0.039 %; 6.72 pmol/L; 2.76 and 3.75 
U/L). Hydroxyurea increased significantly (p < 0.01) the levels of the above-mentioned pro-apoptotic 
proteins relative to those in the normal group. LFPS (100, 200, or 400 mg/kg) reversed significantly (p < 
0.05 or 0.01) the effect of hydroxyurea on all of the above indices. 
Conclusion: LFPS exhibits a protective effect on hydroxyurea-induced ovulation failure by regulating 
the HPO axis hormones and death receptor-mediated apoptotic pathway. 
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Infertility is a common gynecological disease and 
its incidence has gradually increased in recent 
years [1,2]. Infertility, a worldwide social and 
medical problem, is caused by many etiologies, 
including ovulation failure [3-5]. Infertility caused 
by ovulation failure accounts for roughly 25 - 30 
% of infertility cases [6]. 
 
Hormonal ovulation-stimulating drugs are usually 
used to treat ovulation failure in Western 
medicine [7,8]. While the ovulation rate of 
patients increases after treatment with hormonal 
ovulation-stimulating drugs, their pregnancy rate 
is low and there are many adverse reactions 
associated with this type of treatment, such as 
follicular mal-development, ovarian 
hyperstimulation syndrome, internal secretion 
dysfunction, and ovarian cancer [9-11]. By 
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contrast, natural herbal medicines are typically 
used to treat ovulation failure in Chinese 
medicine [12,13] and few adverse reactions 
induced by Chinese medicine have been 
reported [10]. Therefore, Chinese medicine may 
be a possible source of new and effective agents 
for treating ovulation failure. 
 
Lycii Fructus, the fruit of Lycium barbarum L. 
(Solanaceae), is generally used by Chinese 
physicians to treat male infertility and previous 
reports on the effects of Lycii Fructus 
polysaccharides (LFPS) on infertility have 
focused primarily on males [14,15]. The effects of 
LFPS on female infertility caused by ovulation 
failure have thus far remained unknown. 
Therefore, this work was initiated to investigate 
the effects of LFPS on ovulation failure in rats by 
calculating the uterus and ovary indices, 
determining the hypothalamic-pituitary-ovarian 
(HPO) axis hormones, including estradiol (E2) 
level, follicle-stimulating hormone (FSH) activity 
and luteinizing hormone (LH) activity in serum, 
and detecting the levels of pro-apoptotic proteins, 
including Fas, FasL, FADD, cleaved (c)-caspase-
8, c-caspase-10, c-caspase-3, c-caspase-6, and 




Chemicals and reagents 
 
LFPS was obtained from Ningxia Wolfberry 
Biological and Food Engineering Co., Ltd. 
(Yinchuan, China). LFPS was dissolved in 
normal saline to obtain 10, 20, and 40 g/L of 
LFPS for experiments. Hydroxyurea tablets were 
provided by Anter Biopharmaceutical Co., Ltd. 
(Jinzhong, China). Chloral hydrate was obtained 
from Sigma-Aldrich (Shanghai, China). E2, FSH, 
and LH ELISA kits were purchased from 
Shanghai Baili Biotechnology Co., Ltd. 
(Shanghai, China). Enhanced BCA protein assay 
reagent was obtained from Beyotime (Haimen, 
China). Primary antibodies for β-actin, Fas, FasL, 
FADD, c-caspase-8, c-caspase-10, c-caspase-3, 
c-caspase-6, and c-caspase-7, along with HRP-
conjugated goat anti-rabbit antibody were 
obtained from Abcam (Cambridge, UK), Cell 
Signaling Technology (Beverly, MA, USA), or 
Jackson Immuno Research Laboratories (West 
Grove, Pennsylvania, USA). An enhanced 
chemiluminescence detection kit for HRP was 
purchased from Biological Industries (Kibbutz 






Hebetic female SD rats (200 ± 20 g) were 
obtained from the Experimental Animal Center of 
Henan Province (Zhengzhou, China). All animal 
treatments were performed in strict compliance 
with the National Institutes of Health Guide 
concerning the care and use of laboratory 
animals [16]. All experiments in this study were 
approved by Henan Hospital of Traditional 
Chinese Medicine Hospital (Protocol No. 
HNHTCM2011049). 
 
Establishment of ovulation failure model and 
treatment 
 
Hydroxyurea was used to induce ovulation failure 
in rats according to a previous method [17]. 
Hydroxyurea tablet (30 g) was dissolved in 
normal saline (1 L) to obtain a 30 g/L turbid 
hydroxyurea liquid. Rats were administrated 
orally with hydroxyurea at a dose of 300 mg/kg 
once a day for 10 days to establish the ovulation 
failure model. Next, rats with ovulation failure 
were randomly divided into 4 groups: one model 
group and three groups that were administrated 
with different doses of LFPS (n = 10). Rats 
without ovulation failure served as normal group 
(n = 10). Rats in the normal and model groups 
were administrated orally with normal saline once 
a day for 14 days. Rats in the LFPS groups were 
administrated orally with LFPS at doses of 100, 
200, or 400 mg/kg once a day for 14 days, 
respectively. All rat received an intragastric 
volume of 10 mL/kg. 
 
Determination of uterus and ovary indices 
 
After 2 h of drug treatment on 14th day, the rats 
were anesthetized with 10 % chloral hydrate (3 
mL/kg) by intraperitoneal injection. The 5 - 6 mL 
blood from the abdominal aorta of each rat was 
collected using a vacuum blood collection tube. 
After the blood was collected, the rats were 
immediately sacrificed by decapitation. The 
uterus and ovary were then obtained, and their 
surrounding connective and adipose tissues 
were peeled off. Subsequently, the weights of the 
uterus (A) and ovary (B) were measured using 
electronic scales. Based on the body weight of 
the corresponding rat (C), the uterus and ovary 
indices were calculated as Eqs 1 and 2. 
 
Uterus index (%) = (A/C)100……………….. (1) 
Ovary index (%) = (B/C)100….…………….. (2) 
 
Enzyme-linked immunosorbent assay 
 
The collected blood was immediately centrifuged 
at 3000 rpm for 10 min at 4 °C to obtain the 
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serum. Subsequently, the E2 level and the FSH 
and LH activities in the serum were determined 
by using the corresponding ELISA kit according 
to the manufacturers' instructions for each. After 
the reactions were completed, the absorbance 
was determined using a 680Microplate Reader 
(Bio-Rad, USA). The absorbance for these 
indices was used to calculate the level or activity 
according to the corresponding standard curves. 
 
Western blot assay 
 
The total proteins from the ovary tissue were 
extracted, and their concentration was 
determined using enhanced BCA protein assay 
reagent. Equal amounts of proteins (40 μg) were 
separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and blotted 
onto a polyvinylidene difluoride (PVDF) 
membrane. After blocking with 5 % skim milk, the 
PVDF membranes were incubated overnight with 
the corresponding primary antibodies for β-actin, 
Fas, FasL, FADD, c-caspase-8, c-caspase-10, c-
caspase-3, c-caspase-6, and c-caspase-7 at 4 
°C. Subsequently, the PVDF membranes were 
washed with Tris-buffered saline-Tween (TBS-T) 
and incubated with HRP-conjugated goat anti-
rabbit antibody in TBS-T at room temperature for 
2 h. Next, the PVDF membranes were washed 
with TBS-T and incubated with an enhanced 
chemiluminescence detection kit for HRP. The 
bands were detected on x-ray film. β-actin was 





All data are presented as mean ± standard 
deviation (SD). The difference between two 
groups was analyzed by one-way ANOVA 
(Dunnett's test) on SPSS 19.0 (IBM Corporation, 
Armonk, NY, USA). Differences were considered 




Effect of LFPS on uterus and ovary indices in 
rats with ovulation failure 
 
As shown in Table 1, the uterus and ovary 
indices in the model group were reduced 
significantly (p < 0.01), compared with those in 
the normal group. LFPS (100, 200, or 400 mg/kg) 
increased significantly (p < 0.05 or 0.01) the 
uterus and ovary indices relative to those in the 
model group. 
 
Effect of LFPS on E2 level, FSH activity, and 
LH activity in the serum of rats with ovulation 
failure 
 
As shown in Table 2, the E2 level and the FSH 
and LH activities in the model group were 
reduced significantly (p < 0.01) relative to those 
in the normal group. LFPS (100, 200, or 400 
mg/kg) increased significantly (p < 0.05 or 0.01) 
the E2 level and the FSH and LH activities, 
compared with those in the model group. 
 
Effect of LFPS on pro-apoptotic proteins 
levels in the ovary tissue of rats with 
ovulation failure 
 
As shown in Figures 1 and 2, the levels of pro-
apoptotic proteins (Fas, FasL, FADD, c-caspase-
8, c-caspase-10, c-caspase-3, c-caspase-6 and 
c-caspase-7) in the model group were up-
regulated significantly (p < 0.01), compared with  
 
Table 1: LFPS up-regulated uterus and ovary indices in rats with ovulation failure 
 
Group Uterus index (%) Ovary index (%) 
Normal 0.169 ± 0.026 0.039 ± 0.006 
Model 0.119 ± 0.021## 0.026 ± 0.005## 
LFPS 100 mg/kg 0.138 ± 0.019* 0.032 ± 0.006* 
LFPS 200 mg/kg 0.142 ± 0.024* 0.034 ± 0.007** 
LFPS 400 mg/kg 0.147 ± 0.022** 0.037 ± 0.009** 
 ##p < 0.01, compared with those in the normal group; *p < 0.05, **p < 0.01, 
compared with those in the model group 
 
Table 2: LFPS increased E2 level, FSH activity and LH activity in the serum of rats with ovulation failure 
 
Group E2 (pmol/L) FSH (U/L) LH (U/L) 
Normal 6.72 ± 1.95 2.76 ± 0.25 3.75 ± 0.49 
Model 3.42 ± 1.02## 2.28 ± 0.23## 2.76 ± 0.34## 
LFPS 100 mg/kg 4.93 ± 1.34* 2.54 ± 0.21* 3.08 ± 0.29* 
LFPS 200 mg/kg 5.46 ± 1.47** 2.62 ± 0.23** 3.21 ± 0.36* 
LFPS 400 mg/kg 6.04 ± 1.78** 2.71 ± 0.22** 3.51 ± 0.45** 
##p < 0.01, compared with those in the normal group; *p < 0.05, **p < 0.01, compared with 
those in the model group 
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Figure 1: Inhibitory effect of LFPS on Fas, FasL and FADD proteins levels in the ovary tissue of rats with 




Figure 2: Inhibitory effect of LFPS on c-caspase-8, c-caspase-10, c-caspase-3, c-caspase-6 and c-caspase-7 
proteins levels in the ovary tissue of rats with ovulation failure; ##p < 0.01, compared with those in the normal 
group; **p < 0.01, compared with those in the model group 
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those in the normal group. LFPS (100, 200, or 
400 mg/kg) down-regulated significantly (p < 
0.01) these pro-apoptotic proteins levels relative 




It has been reported that LFPS exhibits a 
protective effect on the male reproductive system 
[14,15,18]. However, the effect of LFPS on the 
female reproductive system is unknown. 
Infertility, a common gynecological disease, can 
be caused by dysfunctions of the fallopian tube, 
ovary, uterus, internal secretions, etc. [19,20], 
and ovulation failure is a leading cause of 
infertility [5]. Hydroxyurea is an accepted drug for 
establishing an ovulation failure model in rats 
[21,22]. It has been reported that hydroxyurea 
reduced significantly the uterus and ovary indices 
and down-regulated the levels and activities of 
HPO axis hormones such as E2, FSH and LH 
[13,17]. The ovary was pale following treatment 
with hydroxyurea; hydroxyurea may therefore 
induce ovary tissue apoptosis. 
 
Based on these previous studies, the aim of this 
study was to investigate the effect of LFPS on 
hydroxyurea-induced ovulation failure in rats by 
calculating the uterus and ovary indices, 
determining the E2 level and the FSH and LH 
activities in serum, and detecting the levels of 
pro-apoptotic proteins (Fas, FasL, FADD, c-
caspase-8, c-caspase-10, c-caspase-3, c-
caspase-6, and c-caspase-7) in ovary tissue. 
 
Uterus and ovary indices can visually reflect 
whether the reproductive system is healthy [23]. 
In the present study, we have found that 
hydroxyurea damaged the reproductive system 
of rats by reducing uterus and ovary indices 
(Table 1). However, LFPS maintained the health 
of the reproductive system by inhibiting the 
reduction of uterus and ovary indices. 
 
Dysfunction of the HPO axis and ovary tissue 
apoptosis can result in ovulation failure [17,24]. 
E2, FSH, and LH play important roles in 
maintaining the functions of the HPO axis [25]. 
The main function of E2 is to promote the 
transition of the endometrium from its normal 
condition into its proliferative phase, which 
creates favorable conditions for ovulation. The 
main functions of FSH and LH are to promote 
follicle development and maturation and 
ovulation, respectively [26]. In the present study, 
we have found that hydroxyurea inhibited 
ovulation in rat by down-regulating the E2 level 
and the FSH and LH activities, which were 
reversed by treatment with LFPS (Table 2). 
 
The death receptor-mediated apoptotic pathway 
plays an important role in cell apoptosis [27]. 
Fas, FasL, FADD, c-caspase-8, c-caspase-10, c-
caspase-3, c-caspase-6, and c-caspase-7 are 
the main regulatory proteins in the death 
receptor-mediated apoptotic pathway [27,28]. 
Up-regulations of these proteins levels may 
promote cell apoptosis. In the present study, we 
have found that hydroxyurea induced the 
apoptosis of ovary tissue by up-regulating the 
levels of the above-mentioned pro-apoptotic 





LFPS exhibits a protective effect on hydroxyurea-
induced ovulation failure by regulating HPO axis 
hormones and death receptor-mediated 
apoptotic pathway. Therefore, LFPS may be a 
useful drug candidate to treat ovulation failure. 
However, further studies on the mechanisms by 
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